Atousa Bari, Carrigent, Medical Science Liaison – Cell and Gene Therapy and Viral Vectors, shared post on LinkedIn:
“Recent studies and clinical experience continue to expand the impact of CAR-T therapy.
Approved CAR-T products targeting CD19 and BCMA have revolutionized treatment for hematologic malignancies such as lymphoma, leukemia, and multiple myeloma, achieving high response rates and long-term disease control in relapsed or refractory patients.
The field is now entering a next-generation phase focused on improving safety, durability, and broader applicability.
Advances include:
– Better toxicity management, with refined strategies to control cytokine release syndrome (CRS) and neurotoxicity (ICANS), improving patient safety and enabling earlier intervention.
– Dual-target and multi-target CAR designs, developed to overcome antigen escape and tumor heterogeneity, particularly in aggressive cancers.
– Expansion into solid tumors, historically a major challenge, with emerging clinical trials showing survival improvements and signaling a potential paradigm shift beyond blood cancers.
– AI-guided CAR engineering, accelerating target discovery and molecular optimization for next-generation cellular therapies.
Today, CAR-T therapy stands at the intersection of immunology, gene engineering, and precision medicine. What began as a strategy to reprogram immune cells has evolved into a platform technology that continues to reshape cancer treatment and redefine how personalized medicine is delivered.”
Other articles about CAR-T Therapy on OncoDaily.